What Pharvaris N.V.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 18 | 52 |
| Total trades | 35 | 90 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 70,772 | 166,435 |
| Disposed | 158,325 | 398,696 |
| Net activity | −87,553 | −232,261 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Modig Berndt | Chief Executive Officer | Aug 14 | Open-market sale · S | −2,292 | $34.77 | −$79.7K | 130,625 |
| Lu Peng | President | Aug 12 | Withheld — tax / exercise cost · F | −117 | $34.42 | −$4.03K | 65,179 |
| Lu Peng | President | Aug 11 | Withheld — tax / exercise cost · F | −109 | $34.84 | −$3.8K | 65,296 |
| Modig Berndt | Chief Executive Officer | Jul 13 | Disclosed 10b5-1 sale · S | −2,292 | $34.97 | −$80.2K | 132,917 |
| Lu Peng | Chief Medical Officer | Jul 12 | Withheld — tax / exercise cost · F | −117 | $35.07 | −$4.1K | 65,405 |
| Lu Peng | Chief Medical Officer | Jul 11 | Withheld — tax / exercise cost · F | −109 | $35.07 | −$3.82K | 65,522 |
| Lesage Anne | Chief Early Development | Jun 30 | Disclosed 10b5-1 sale · S | −30,703 | $35.49 | −$1.09M | 93,969 |
| Lesage Anne | Chief Early Development | Jun 30 | Disclosed 10b5-1 sale · S | −27,872 | $35.48 | −$989K | 58,750 |
| Lesage Anne | Chief Early Development | Jun 30 | Exercise / conversion · M | +24,900 | $8.05 | +$200K | 86,622 |
| Lesage Anne | Chief Early Development | Jun 30 | Exercise / conversion · M | +2,972 | $2.59 | +$7.7K | 61,722 |
| Schikan Johannes Gerardus Christiaan Petrus | Director | Jun 30 | Disclosed 10b5-1 sale · S | −30,712 | $35.49 | −$1.09M | 315,167 |
| Lesage Anne | Chief Early Development | Jun 29 | Disclosed 10b5-1 sale · S | −6,997 | $35.05 | −$245K | 124,672 |
| Lesage Anne | Chief Early Development | Jun 29 | Disclosed 10b5-1 sale · S | −8,300 | $35.05 | −$291K | 58,750 |
| Lesage Anne | Chief Early Development | Jun 29 | Disclosed 10b5-1 sale · S | −2,300 | $35.12 | −$80.8K | 56,450 |
| Lesage Anne | Chief Early Development | Jun 29 | Exercise / conversion · M | +4,200 | $8.05 | +$33.8K | 67,050 |
| Lesage Anne | Chief Early Development | Jun 29 | Exercise / conversion · M | +4,100 | $2.59 | +$10.6K | 56,450 |
| Lesage Anne | Chief Early Development | Jun 29 | Exercise / conversion · M | +900 | $8.05 | +$7.25K | 58,750 |
| Lesage Anne | Chief Early Development | Jun 29 | Exercise / conversion · M | +1,400 | $2.59 | +$3.63K | 57,850 |
| Schikan Johannes Gerardus Christiaan Petrus | Director | Jun 29 | Disclosed 10b5-1 sale · S | −6,888 | $35.05 | −$241K | 345,879 |
| Schikan Johannes Gerardus Christiaan Petrus | Director | Jun 29 | Disclosed 10b5-1 sale · S | −2,400 | $35.10 | −$84.2K | 352,767 |
Loading...